6I9I

Rift valley fever virus Gn in complex with a neutralizing antibody fragment


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.98 Å
  • R-Value Free: 0.243 
  • R-Value Work: 0.203 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus.

Allen, E.R.Krumm, S.A.Raghwani, J.Halldorsson, S.Elliott, A.Graham, V.A.Koudriakova, E.Harlos, K.Wright, D.Warimwe, G.M.Brennan, B.Huiskonen, J.T.Dowall, S.D.Elliott, R.M.Pybus, O.G.Burton, D.R.Hewson, R.Doores, K.J.Bowden, T.A.

(2018) Cell Rep 25: 3750-3758.e4

  • DOI: 10.1016/j.celrep.2018.12.001

  • PubMed Abstract: 
  • The Gn subcomponent of the Gn-Gc assembly that envelopes the human and animal pathogen, Rift Valley fever virus (RVFV), is a primary target of the neutralizing antibody response. To better understand the molecular basis for immune recognition, we rai ...

    The Gn subcomponent of the Gn-Gc assembly that envelopes the human and animal pathogen, Rift Valley fever virus (RVFV), is a primary target of the neutralizing antibody response. To better understand the molecular basis for immune recognition, we raised a class of neutralizing monoclonal antibodies (nAbs) against RVFV Gn, which exhibited protective efficacy in a mouse infection model. Structural characterization revealed that these nAbs were directed to the membrane-distal domain of RVFV Gn and likely prevented virus entry into a host cell by blocking fusogenic rearrangements of the Gn-Gc lattice. Genome sequence analysis confirmed that this region of the RVFV Gn-Gc assembly was under selective pressure and constituted a site of vulnerability on the virion surface. These data provide a blueprint for the rational design of immunotherapeutics and vaccines capable of preventing RVFV infection and a model for understanding Ab-mediated neutralization of bunyaviruses more generally.


    Organizational Affiliation

    Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
RV-Gn1 Heavy chain
A, H
223N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
RV-Gn1 Light chain
B, L
217N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
Glycoprotein
C
325Rift valley fever virusMutation(s): 0 
Find proteins for A2T080 (Rift valley fever virus)
Go to UniProtKB:  A2T080
Entity ID: 4
MoleculeChainsSequence LengthOrganismDetails
Glycoprotein
D
324Rift valley fever virusMutation(s): 0 
Find proteins for A2T080 (Rift valley fever virus)
Go to UniProtKB:  A2T080
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.98 Å
  • R-Value Free: 0.243 
  • R-Value Work: 0.203 
  • Space Group: P 1
Unit Cell:
Length (Å)Angle (°)
a = 51.590α = 81.01
b = 61.950β = 77.52
c = 78.910γ = 84.74
Software Package:
Software NamePurpose
xia2data scaling
REFMACrefinement
xia2data reduction
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Medical Research Council (United Kingdom)United KingdomMR/N002091/1
Medical Research Council (United Kingdom)United KingdomMR/J007897/1

Revision History 

  • Version 1.0: 2018-12-26
    Type: Initial release
  • Version 1.1: 2019-01-09
    Type: Data collection, Database references